Assessment of Chk1 phosphorylation as a pharmacodynamic biomarker of Chk1 inhibition

PURPOSE: Chk1 inhibitors, such as AZD7762 are in clinical development in combination with cytotoxic agents for the treatment of solid tumors, including pancreatic cancers. To maximize the likelihood of their clinical success, it is essential to optimize drug scheduling as well as pharmacodynamic bio...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Parsels, Leslie A., Qian, Yushen, Tanska, Daria M., Gross, Marisa, Zhao, Lili, Hassan, Maria C., Arumugarajah, Sankari, Parsels, Joshua D., Hylander-Gans, Linda, Simeone, Diane M., Morosini, Deborah, Brown, Jeffrey L., Zabludoff, Sonya D., Maybaum, Jonathan, Lawrence, Theodore S., Morgan, Meredith A.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2011
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3107893/
https://ncbi.nlm.nih.gov/pubmed/21482692
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-10-3082
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge